IGC
Igc Pharma Inc
AMEX · Pharmaceuticals
$0.25
+0.00 (+0.81%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 13.24M | 13.95M | 13.36M |
| Net Income | 1.80M | 2.16M | 1.76M |
| EPS | — | — | — |
| Profit Margin | 13.6% | 15.5% | 13.2% |
| Rev Growth | +11.8% | +17.1% | -6.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 11.84M | 9.96M | 10.38M |
| Total Equity | 16.55M | 19.20M | 17.06M |
| D/E Ratio | 0.72 | 0.52 | 0.61 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 3.50M | 3.52M | 3.64M |
| Free Cash Flow | 1.97M | 2.06M | 1.63M |